HKU Scholars Hub: Browsing DSpace

Browsing by Author Thi, EP

Jump to: 0-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z 中

or enter first few letters:

Showing results 1 to 13 of 13

	Title	Author(s)	Issue Date
	A single dose of the GalNAc-siRNA, AB-729, results in prolonged reductions in HBsAg, HBcrAg, HBV DNA and HBV RNA in the absence of nucleos (t)ide analogue therapy in HBeAg negative subjects with chronic hepatitis B infection Proceeding/Conference:Journal of Hepatology	Gane, E Sevinsky, H Yuen, RMF Anderson, M Cloherty, G Thi, EP Wattamwar, T Sofia, MJ Gray, K Antoniello, D Eley, T Picchio, G Sims, K	2021
	AB-729, a GalNAc-siRNA, results in robust reductions of HBV DNA and HBsAg in subjects with chronic hepatitis B infection Proceeding/Conference:Hepatology International	Sevinsky, H Gane, ED Gane, E Berliba, E Kim, YJ Holmes, J Lim, Y-S Strasser, S Sukeepaisarnjaroen, W Schwabe, C Jucov, A Lee, ACH Thi, EP Harasym, T Pamulapati, GR Wattamwar, P Kunta, J Sofia, M Sevinsky, H Gray, K Eley, T Picchio, G Sims, KD Yuen, RMF	2021
	Continued suppression of viral markers observed following discontinuation of nucleos (t)ide analogue therapy in chronic hepatitis B subjects with low hepatitis B surface antigen levels after 48 weeks of treatment with AB-729. Poster Presentation (SAT 448) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology	Yuen, RMF Strasser, S Sukeepaisarnjaroen, W Sharma, V Antoniello, D Medvedeva, E Thi, EP Picchio, G Eley, T Sims, K	2022
	Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 in chronic hepatitis B patients correlates with suppression of all HBsAg isoforms and HBV RNA Proceeding/Conference:Journal of Hepatology	Thi, EP Yuen, RMF Gane, E Sevinsky, H Sims, K Anderson, M Lam, AM Sofia, MJ Cloherty, G Picchio, G	2021
	Inhibition of hepatitis B surface antigen by RNA interference therapeutic AB-729 is associated with increased cytokine signatures in HBV DNA+ chronic hepatitis B patients. Poster Presentation (SAT396) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology	Ganchua, S Paratala, B Iott, C Yuen, RMF Gane, EJ Eley, T Sims, K Gray, K Antoniello, D Lam, AM Sofia, MJ Picchio, G Thi, EP	2022
	Inhibition of hepatitis B surface antigen in chronic hepatitis B subjects by RNA interference therapeutic AB-729 is accompanied by upregulation of HBV-specific T cell activation markers Proceeding/Conference:Journal of Hepatology	Paratala, B Park, J-J Ganchua, SC Gane, E Yuen, RMF Lee, ACH Moore, C Lam, AM Sevinsky, H Sims, K Antoniello, D Sofia, MJ Picchio, G Thi, EP	2021
	Long-term suppression maintained after cessation of AB-729 treatment and comparable on-treatment response observed in HBeAg+ subjects. Poster Presentation (SAT443) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology	Yuen, RMF Berliba, E Sukeepaisarnjaroen, W Holmes, J Leerapun, A Tangkijvanich, P Strasser, S Jucov, A Gane, EJ Thi, EP Sevinsky, N Medvedeva, E Sharma, V Gray, K Antoniello, D Picchio, G Sims, K Eley, T	2022
	Reduction of hepatitis B surface antigen mediated by RNA interference therapeutic AB-729 in chronic hepatitis B patients is associated with T cell activation and a decline in exhausted CD8 T cells. Poster Presentation (SAT397) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology	Ganchua, SC Paratala, B Iott, C Gane, EJ Yuen, RMF Eley, T Sims, K Gray, K Antoniello, D Lam, AM Sofia, MJ Picchio, G Thi, EP	2022
	Repeat dosing of the GalNAc-siRNA AB-729 in subjects with chronic hepatitis B results in robust and sustained HBsAg suppression Proceeding/Conference:Journal of Hepatology	Yuen, RMF Berliba, E Sukeepaisarnjaroen, W Strasser, S Tangkijvanich, P Holmes, J Leerapun, A Jucov, A Thi, EP Wattamwar, T Sofia, MJ Sevinsky, H Gray, K Antoniello, D Eley, T Picchio, G Sims, K Gane, E	2021
	Safety and pharmacodynamics of the GALNAC-siRNA AB-729 in subjects with chronic hepatitis B infection Proceeding/Conference:Hepatology	Yuen, RMF Berliba, E Kim, YJ Holmes, JA Lim, YS Strasser, SI Schwabe, C Jucov, A Lee, ACH Thi, EP Harasym, T Pamulapati, GR Wattamwar, P Kunta, J Sofia, MJ Sevinsky, H Gray, K Eley, T Picchio, GR Sims, K Gane, EJ	2020
	Safety, pharmacokinetics, and antiviral activity of the capsid inhibitor AB-506 from Phase 1 studies in healthy subjects and those with hepatitis B Journal:Hepatology Communications	Yuen, MF Berliba, E Sukeepaisarnjaroen, W Ahn, SH Tanwandee, T Lim, YS Kim, YJ Poovorawan, K Tangkijvanich, P Schwabe, C Eley, T Brown, J Lee, ACH Thi, EP Paratala, B Mani, N Sofia, MJ Picchio, G Sims, KD Gane, EJ	4-Oct-2022
	Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the 3rd generation capsid inhibitor AB-836 in healthy subjects(HS) and subjects with chronic hepatitis B (CHB). Poster Presentation (SAT392) Proceeding/Conference:The International Liver Congress 2022, 22-26 June 2022. Journal of Hepatology	Gane, EJ Jucov, A Kolomiichuk, L Eley, T Brown, J King, Y Medvedeva, E Chernyakhovskyy, M Mani, N Cole, AG Kultgen, SG Pamulapati, R Thi, EP Harasym, TO Dugyala, R Chaudhari, S Sofia, MJ Child, M Picchio, G Sims, K Yuen, RMF	2022
	Safety, tolerability, pharmacokinetics (PK), and antiviral activity of the capsid inhibitor (CI) AB-506 in healthy subjects (HS) and chronic hepatitis B (CHB) subjects Proceeding/Conference:Hepatology	Yuen, RMF Berliba, E Sukeepaisarnjaroen, W Ahn, SH Tanwandee, T Lim, Y-S Kim, YJ Poovorawan, K Tangkijvanich, P Chan, HLY Eley, T Brown, J Moore, C Lee, ACH Kim, J Thi, EP Mani, N Rijnbrand, R Cole, A Sofia, MJ Picchio, GR Sims, K Gane, EJ	2019

Showing results 1 to 13 of 13